1. Andexanet Alfa: What We Have Learned from Clinical Trials and Real-World Data

   • Senta Frol
   • Janja Pretnar Oblak
   • Pawel Kermer

   Current Opinion 23 February 2024 Pages: 163 - 168

2. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis

   • Yue Qiao
   • Jian Gu
   • Ying Ma

   Systematic Review 01 March 2024 Pages: 169 - 192

   

3. Unmet Needs in Psychodermatology: A Narrative Review

   • Rachel E. Christensen
   • Mohammad Jafferany

   Review Article 22 February 2024 Pages: 193 - 204

4. Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis

   • Anastasiia D. Shkodina
   • Mainak Bardhan
   • Mykhailo Yu. Delva

   Review Article 29 February 2024 Pages: 205 - 224

   

5. Early Experiences with Intrathecal Administration of Amphotericin B Liposomal Formulation at a Neurosurgical Center

   • Michael D. Nailor
   • Kellie J. Goodlet
   • J. Tyler Haller

   Original Research 25 January 2024 Pages: 225 - 229

6. Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study

   • Lucienne Costa-Frossard França
   • Virginia Meca Lallana
   • José Manuel García Domínguez

   Original Research Article Open access 28 February 2024 Pages: 231 - 238